Ledger.Open graph →
SEC Form D · Amendment · filed December 16, 2025

Imbria Pharmaceuticals, Inc

Offering
$144.2M
Sold
$66.7M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
BOSTON, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (20)

Alvin Shih · Boston, MAExec · DirectorKomal Joshi · Boston, MAExecAndrew Levin · Boston, MADirectorCharles Dunn · Boston, MADirectorAndrew Levin · Boston, MADirectorCharles Dunn · Boston, MADirectorAlvin Shih · Boston, MAExec · DirectorKomal Joshi · Boston, MAExecPavan Cheruvu · Boston, MADirectorLuse Rebecca · Boston, MADirectorKen Horne · Boston, MADirectorZina Affas Besse · Woodland Hills, CADirectorKeith Grimes · Houston, TXExecEdward Gillespie · Houston, TXExec · DirectorPeter Longo · Houston, TXDirectorLucie Harwood · Houston, TXDirectorPavan Cheruvu · Boston, MADirectorLuse Rebecca · Boston, MADirectorKen Horne · Boston, MADirectorZina Affas Besse · Woodland Hills, CADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗